Lipocine Inc.
About Lipocine Inc.
Lipocine Inc is a clinical-stage biopharmaceutical company that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates, or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy (TRT). It also has other products in the pipeline, such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $2.0M
- Net income
- -$9.6M
- Total assets
- $17.0M
- Market cap
- $16.9M
- Operating margin
- -524.7%
- Net margin
- -487.1%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $2.0M
- Operating expenses
- $12.3M
- Operating income
- -$10.4M
- Income tax
- $200
- Net income
- -$9.6M
Balance sheet
- Total assets
- $17.0M
- Current assets
- $16.9M
- Total liabilities
- $2.5M
- Current liabilities
- $2.5M
- Shareholders’ equity
- $14.5M
Cash flow
- Operating cash flow
- -$9.8M
- Investing cash flow
- $5.9M
- Financing cash flow
- $2.9M
- Net cash flow
- -$1.0M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $16.9M
- Shares outstanding
- 8.3M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jun 5, 2012
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $9.6M in FY2025.
- Revenue declined 88% from FY2021 to FY2025.
- Trading 82% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Lipocine Inc..
Write a review
News about Lipocine Inc.
News & sentiment via Polygon.io
